MET-inhibiting TKIs, such as capmatinib and tepotinib, have shown promising results in clinical trials for NSCLC patients with METex14 or MET amplification, leading to accelerated FDA approvals [43,44]. The gene discussed is MET; the disease is non-small cell lung carcinoma.